VAXELIS Drug Profile

Summary for Tradename: VAXELIS

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for VAXELIS

Recent Clinical Trials for VAXELIS

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Merck Sharp & Dohme Corp.	Phase 4
Johns Hopkins Bloomberg School of Public Health	Phase 4
Merck Sharp & Dohme Corp.	Phase 3

See all VAXELIS clinical trials

Pharmacology for VAXELIS

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Inactivated Bordetella Pertussis Vaccine Inactivated Clostridium Tetani Vaccine Inactivated Corynebacterium Diphtheriae Vaccine Inactivated Haemophilus Influenzae B Vaccine Inactivated Hepatitis B Virus Vaccine Inactivated Poliovirus Vaccine
Chemical Structure	Diphtheria Toxoid Haemophilus Vaccines Hepatitis B Vaccines Pertussis Vaccine Poliovirus Vaccines Tetanus Toxoid Vaccines, Inactivated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for VAXELIS Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for VAXELIS Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for VAXELIS Derived from Patent Text Search

No patents found based on company disclosures